Study summary

A once-daily pill kept about half of responders in remission for nearly a year

ABTECT maintenance trial · Phase 3, two induction trials plus maintenance · Topline results 2026; FDA filing planned late 2026

51%in remission at 44 weeks, vs 10% with placebo

What was tested

Obefazimod, a once-daily pill that boosts a natural anti-inflammatory microRNA, against placebo, as maintenance treatment after initial response.

What they found

Remission at 44 weeks was about 51% vs 10% with placebo.
People who didn't respond to the first round of treatment still benefited from continuing it.
No new safety signals through 44 weeks.

What it means

Would be the first new oral mechanism for ulcerative colitis in years, pending FDA review.

Sofinnova Partners / company release ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.